Get all premium features to the best stock analysis tool

$201.2 Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow Potential UNIONDALE, NY, April 15, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and consumer products company, today reported its financial results for the year ended December 31, 2025 and provided a business update highlighting continued advancement and expansion of its Crown Medical Collections initiative. “We are very encouraged by the scale and progression of activity across our receivables platform,” said Ted Karkus, Chief Executive Officer of ProPhase Labs.

UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company's underlying asset base.

Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company.

ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection Transcript

UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature ProPhase Lab's Chairman and CEO Ted Karkus.

ProPhase Labs, Inc. ( PRPH ) Q3 2025 Earnings Call November 19, 2025 2:00 PM EST Company Participants Ted Karkus - Chairman & CEO Presentation Operator Hello, and good afternoon, everyone. Welcome to today's presentation.

ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important.